JeanLuc Belingard - Laboratory Independent Director
LH Stock | USD 207.94 0.03 0.01% |
Director
Mr. JeanLuc Belingard is Independent Director of the Company. He has served as a director of the Company since April 28, 1995. From 2011 to December 2017, Mr. Blingard served as Chairman of bioMrieux, the worldwide leader of the IVD microbiology segment and a nonU.S. public company since 2010. Mr. Blingard continues to serve on the board of directors of bioMrieux and as Vice President of Institut Mrieux. Prior to serving as Chairman, Mr. Blingard had served as Chief Executive Officer of bioMrieux from July 2011 to April 2014. Mr. Blingard retired as Chairman and Chief Executive Officer of Ipsen SA, a diversified French healthcare holding company, on November 22, 2010. He had served in that position since 2002. Prior to this position, Mr. Blingard was Chief Executive Officer from 1999 to 2001 of bioMrieuxPierre Fabre, a diversified French healthcare holding company, where his responsibilities included the management of that companys worldwide pharmaceutical and cosmetic business. From 1990 to 1999, Mr. Blingard was Chief Executive Officer of Roche Diagnostics and a member of the Hoffman La Roche group Executive Committee. Mr. Blingard is a director of the following nonUS public companies Stallergenes Greer since 2011, Transgene SA since 2013, and Lupin Limited . Mr. Blingard holds directorships at various Institut Mrieux Group companies, in particular at Institut Mrieux, the Groups parent company. Mr. Blingard serves on the advisory board of Laboratoire Pierre Fabre S.A. since 2013, which is owned by The Pierre Fabre Foundation, a governmentrecognized public organization. Mr. Blingard is also a member of the Bill and Melinda Gates Foundation CEO Roundtable. Mr. Blingard was Chairman of FEFIS, the French Federation of Health Industries since 2016, and, since January 2017, he was a member of the Conseil National de lIndustrie chaired by the French government. since 1995.
Age | 72 |
Tenure | 29 years |
Address | 358 South Main Street, Burlington, NC, United States, 27215 |
Phone | 336 229 1127 |
Web | https://www.labcorp.com |
Laboratory Management Efficiency
The company has Return on Asset (ROA) of 0.0377 % which means that for every $100 of assets, it generated a profit of $0.0377. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0423 %, which means that it produced $0.0423 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.08. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Charles OData | Fonar | 82 | |
Brian Gibson | Prenetics Global | 58 | |
Yalon Farhi | DarioHealth Corp | 54 | |
Robin Sidders | Prenetics Global | N/A | |
Robert Janoff | Fonar | 90 | |
Debra Perry | Prenetics Global | 64 | |
Ori Zanco | DarioHealth Corp | N/A | |
Bryan Reasons | Aclaris Therapeutics | 50 | |
Remy Sautter | Prenetics Global | 69 | |
Glen Moller | DarioHealth Corp | N/A | |
Dennis McGrath | DarioHealth Corp | 60 | |
Jan Holsboer | Prenetics Global | 68 | |
Albert Cha | Aclaris Therapeutics | 42 | |
Steven Krablin | Prenetics Global | 64 | |
Roberto Mendoza | Prenetics Global | 67 | |
Kevin Twomey | Prenetics Global | 67 | |
Daniel Culver | Fonar | N/A | |
Allen Kamer | DarioHealth Corp | 45 | |
Richard Bierly | Aclaris Therapeutics | 60 | |
Stephen Letwin | Prenetics Global | 59 | |
Rami Yehudiha | DarioHealth Corp | 46 |
Management Performance
Return On Equity | 0.0423 | ||||
Return On Asset | 0.0377 |
Laboratory Leadership Team
Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
William Klitgaard, President- Enlighten Health | ||
Paul Surdez, IR Contact Officer | ||
Deborah Tanner, CEO - Covance Drug Development (Covance) | ||
Stephen Anderson, Vice President Investor Relations | ||
Sanders Williams, Independent Director | ||
JD MD, President EVP | ||
Amy Summy, Executive Vice President Chief Marketing Officer | ||
Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | ||
Robert Pringle, Senior Treasurer | ||
Peter Wilkinson, Senior Vice President, Chief Accounting Officer | ||
Lisa Uthgenannt, Chief Human Resource Officer, Senior Vice President | ||
Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer | ||
D Gilliland, Independent Director | ||
Gary Huff, CEO, LabCorp Diagnostics | ||
JeanLuc Belingard, Independent Director | ||
Clarissa Willett, IR Contact Officer | ||
Peter Neupert, Lead Independent Director | ||
Robert Williams, Independent Director | ||
Megan MPH, Executive Officer | ||
Chas Cook, VP Relations | ||
Garheng Kong, Independent Director | ||
Gary Gilliland, Independent Director | ||
David King, Chairman of the Board, President, Chief Executive Officer | ||
Adam Schechter, Chairman of the Board, President, Chief Executive Officer | ||
Mark Brecher, Senior Vice President Chief Medical Officer | ||
Samuel Eberts, Senior Vice President Chief Compliance Officer, Secretary, Chief Legal Officer | ||
Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||
Edward Dodson, Chief Accounting Officer and Sr. VP | ||
Robert Mittelstaedt, Lead Independent Director | ||
Anita Graham, Executive Officer | ||
Glenn Eisenberg, Chief Financial Officer, Executive Vice President | ||
Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
Judith Seltz, Chief Human Resource Officer, Executive Vice President | ||
Michelle Abelson, Laboratory Operations | ||
Jonathan DiVincenzo, Executive International | ||
John Ratliff, Chief Executive Officer - Covance Drug Development | ||
Kerrii Anderson, Independent Director | ||
Paul MD, Ex Devel | ||
Marcia Eisenberg, Chief VP | ||
John Treadwell, Vice Initiatives | ||
Kathryn Wengel, Independent Director | ||
Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development | ||
James Boyle, Executive VP and CEO of Labcorp Diagnostics | ||
Richelle Parham, Independent Director | ||
Jeffrey Davis, Independent Director | ||
Christin ODonnell, Vice Relations | ||
Deborah SesokPizzini, SVP Officer | ||
Scott Frommer, Vice President - Investor Relations | ||
MPH MD, Pres VP |
Laboratory Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0423 | ||||
Return On Asset | 0.0377 | ||||
Profit Margin | 0.03 % | ||||
Operating Margin | 0.07 % | ||||
Current Valuation | 22.92 B | ||||
Shares Outstanding | 84.13 M | ||||
Shares Owned By Insiders | 0.34 % | ||||
Shares Owned By Institutions | 98.97 % | ||||
Number Of Shares Shorted | 1.92 M | ||||
Price To Earning | 12.69 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Laboratory information on this page should be used as a complementary analysis to other Laboratory's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Laboratory's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.46) | Dividend Share 2.88 | Earnings Share 4.33 | Revenue Per Share 139.628 | Quarterly Revenue Growth 0.035 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.